Revance Therapeutics, Inc. (Nasdaq: RVNC) announced a proposed underwritten public offering of 3,000,000 shares of its common stock pursuant to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE